Exenatide for type 2 diabetes proves effective in Phase II trial
About two-thirds of individuals in the U.S. are either overweight or obese, and this may account for the rising prevalence of associated health conditions such as type 2 diabetes.
About two-thirds of individuals in the U.S. are either overweight or obese, and this may account for the rising prevalence of associated health conditions such as type 2 diabetes. Patients with this ailment often buy Actos and other drugs to improve their glycemic control, and a new drug from Amylin Pharmaceuticals is expected to have the same effect.
In a recent Phase II clinical trial, the remedy - called exenatide - had a positive impact on the glucose levels of 121 diabetics. After 20 weeks of treatment, participants experienced significant reductions in their average blood sugar.
"We are now developing once-weekly and once-monthly formulations of exenatide to expand patient choices for improving glycemic control," said researcher Christian Weyer. "Based on the encouraging results of this study, we plan to proceed with regulatory interactions to outline the next steps for this important program."
The team reported that minor side effects such as headache and nausea were experienced by some of the patients, but that none of them reported experiencing major or minor hypoglycemia.
In addition to such newly developed drugs, type 2 diabetics have a wealth of medications available to help alleviate their symptoms. Searching for the products they need through a Canadian online pharmacy could help them find affordable options.
|
